{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:12:16Z","timestamp":1767143536353,"version":"build-2238731810"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12012-018-9459-x","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T12:21:04Z","timestamp":1526646064000},"page":"482-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"18","author":[{"given":"Nejat","family":"Mahdieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ata","family":"Firouzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Zahedmehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Hoseinimoghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedigheh","family":"Saedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Sanati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosseinali","family":"Basiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feridoun","family":"Noohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahareh","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"9459_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1039\/C6MB00115G","volume":"12","author":"B Rabbani","year":"2016","unstructured":"Rabbani, B., Nakaoka, H., Akhondzadeh, S., Tekin, M., & Mahdieh, N. (2016). Next generation sequencing: Implications in personalized medicine and pharmacogenomics. Molecular BioSystems, 12, 1818\u20131830.","journal-title":"Molecular BioSystems"},{"key":"9459_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/323728a0","volume":"323","author":"P Gros","year":"1986","unstructured":"Gros, P., Ben Neriah, Y. B., Croop, J. M., & Housman, D. E. (1986). Isolation and expression of a complementary DNA that confers multidrug resistance. Nature, 323, 728\u2013731.","journal-title":"Nature"},{"key":"9459_CR3","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","volume":"117","author":"M Cattaneo","year":"2011","unstructured":"Cattaneo, M. (2011). The platelet P2Y(1)(2) receptor for adenosine diphosphate: Congenital and drug-induced defects. Blood, 117, 2102\u20132112.","journal-title":"Blood"},{"key":"9459_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","volume":"81","author":"NA Farid","year":"2007","unstructured":"Farid, N. A., Payne, C. D., Small, D. S., Winters, K. J., Ernest, C. S. 2nd, Brandt, J. T., et al. (2007). Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical Pharmacology & Therapeutics, 81, 735\u2013741.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9459_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1124\/dmd.31.1.53","volume":"31","author":"TA Clarke","year":"2003","unstructured":"Clarke, T. A., & Waskell, L. A. (2003). The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism and Disposition, 31, 53\u201359.","journal-title":"Drug Metabolism and Disposition"},{"key":"9459_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabolism and Disposition, 38, 92\u201399.","journal-title":"Drug Metabolism and Disposition"},{"key":"9459_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","volume":"19","author":"J Geiger","year":"1999","unstructured":"Geiger, J., Brich, J., Honig-Liedl, P., Eigenthaler, M., Schanzenbacher, P., Herbert, J. M., et al. (1999). Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2007\u20132011.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9459_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"FG Kushner","year":"2009","unstructured":"Kushner, F. G., Hand, M., Smith, S. C. Jr., King, S. B. 3rd, Anderson, J. L., Antman, E. M., et al. (2009). 2009 focused updates: ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 120, 2271\u20132306.","journal-title":"Circulation"},{"key":"9459_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., et al. (2013). Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics, 94, 317\u2013323.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9459_CR10","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O\u2019Connor, C. M. (2003). Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107, 2908\u20132913.","journal-title":"Circulation"},{"key":"9459_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","volume":"9","author":"T Geisler","year":"2008","unstructured":"Geisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., et al. (2008). CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 9, 1251\u20131259.","journal-title":"Pharmacogenomics"},{"key":"9459_CR12","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt, J. T., Close, S. L., Iturria, S. J., Payne, C. D., Farid, N. A., Ernest, C. S. 2nd, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis, 5, 2429\u20132436.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9459_CR13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM Morais De","year":"1994","unstructured":"De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594\u2013598.","journal-title":"Molecular Pharmacology"},{"key":"9459_CR14","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM Morais de","year":"1994","unstructured":"de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419\u201315422.","journal-title":"Journal of Biological Chemistry"},{"key":"9459_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1503\/cmaj.060664","volume":"174","author":"JW Suh","year":"2006","unstructured":"Suh, J. W., Koo, B. K., Zhang, S. Y., Park, K. W., Cho, J. Y., Jang, I. J., et al. (2006). Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Canadian Medical Association Journal, 174, 1715\u20131722.","journal-title":"Canadian Medical Association Journal"},{"key":"9459_CR16","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","volume":"376","author":"JL Mega","year":"2010","unstructured":"Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Walker, J. R., Simon, T., et al. (2010). Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet, 376, 1312\u20131319.","journal-title":"Lancet"},{"key":"9459_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1135308","volume":"315","author":"C Kimchi-Sarfaty","year":"2007","unstructured":"Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., et al. (2007). A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525\u2013528.","journal-title":"Science"},{"key":"9459_CR18","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","volume":"26","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Cavallari, U., Trabetti, E., et al. (2006). Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1895\u20131900.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9459_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner, A. R., O\u2019Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302, 849\u2013857.","journal-title":"JAMA"},{"key":"9459_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. The New England Journal of Medicine, 360, 363\u2013375.","journal-title":"The New England Journal of Medicine"},{"key":"9459_CR21","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 97, 3473\u20133478.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9459_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","volume":"15","author":"D Wang","year":"2005","unstructured":"Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Sadee, W. (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C> T affects mRNA stability. Pharmacogenet Genomics, 15, 693\u2013704.","journal-title":"Pharmacogenet Genomics"},{"key":"9459_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jcph.323","volume":"54","author":"M Karazniewicz-Lada","year":"2014","unstructured":"Karazniewicz-Lada, M., Danielak, D., Rubis, B., Burchardt, P., Oszkinis, G., & Glowka, F. (2014). The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. The Journal of Clinical Pharmacology, 54, 874\u2013880.","journal-title":"The Journal of Clinical Pharmacology"},{"key":"9459_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13318-016-0324-7","volume":"42","author":"D Danielak","year":"2017","unstructured":"Danielak, D., Karazniewicz-Lada, M., Wisniewska, K., Bergus, P., Burchardt, P., Komosa, A., et al. (2017). Impact of CYP3A4*1G Allele on clinical pharmacokinetics and pharmacodynamics of clopidogrel. The European Journal of Drug Metabolism and Pharmacokinetics, 42, 99\u2013107.","journal-title":"The European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"9459_CR25","doi-asserted-by":"publisher","first-page":"8062796","DOI":"10.1155\/2017\/8062796","volume":"2017","author":"AM Amin","year":"2017","unstructured":"Amin, A. M., Sheau Chin L., Azri Mohamed Noor D., Kader S. A., Ali M., Kah Hay Y, et al. (2017). The personalization of clopidogrel antiplatelet therapy: The role of integrative pharmacogenetics and pharmacometabolomics. Cardiology Research and Practice 2017, 8062796.","journal-title":"Cardiology Research and Practice"},{"key":"9459_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","volume":"15","author":"N Shirai","year":"2001","unstructured":"Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., et al. (2001). Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Alimentary Pharmacology & Therapeutics, 15, 1929\u20131937.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"9459_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0009-9236(99)70075-5","volume":"65","author":"T Furuta","year":"1999","unstructured":"Furuta, T., Ohashi, K., Kosuge, K., Zhao, X. J., Takashima, M., Kimura, M., et al. (1999). CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clinical Pharmacology & Therapeutics, 65, 552\u2013561.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9459_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clpt.2004.05.002","volume":"76","author":"M Schwab","year":"2004","unstructured":"Schwab, M., Schaeffeler, E., Klotz, U., & Treiber, G. (2004). CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clinical Pharmacology & Therapeutics, 76, 201\u2013209.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9459_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim, S. C., Risinger, C., Dahl, M. L., Aklillu, E., Christensen, M., Bertilsson, L., et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology & Therapeutics, 79, 103\u2013113.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"9459_CR30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin, L., James, S., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J., et al. (2010). Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet, 376, 1320\u20131328.","journal-title":"Lancet"},{"key":"9459_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans, W. E., & McLeod, H. L. (2003). Pharmacogenomics\u2013drug disposition, drug targets, and side effects. The New England Journal of Medicine, 348, 538\u2013549.","journal-title":"The New England Journal of Medicine"},{"key":"9459_CR32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/dmd.31.7.938","volume":"31","author":"KC Patki","year":"2003","unstructured":"Patki, K. C., Von Moltke, L. L., & Greenblatt, D. J. (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: Role of cyp3a4 and cyp3a5. Drug Metabolism and Disposition, 31, 938\u2013944.","journal-title":"Drug Metabolism and Disposition"},{"key":"9459_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/hrt.2009.171488","volume":"96","author":"T Gremmel","year":"2010","unstructured":"Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2010). Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart, 96, 186\u2013189.","journal-title":"Heart"},{"key":"9459_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jacc.2010.08.640","volume":"57","author":"JB Olesen","year":"2011","unstructured":"Olesen, J. B., Gislason, G. H., Charlot, M. G., Fosbol, E. L., Andersson, C., Weeke, P., et al. (2011). Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: A nationwide cohort study. Journal of the American College of Cardiology, 57, 409\u2013417.","journal-title":"Journal of the American College of Cardiology"},{"key":"9459_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ahj.2010.11.010","volume":"161","author":"N Sarafoff","year":"2011","unstructured":"Sarafoff, N., Neumann, L., Morath, T., Bernlochner, I., Mehilli, J., Schomig, A., et al. (2011). Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. American Heart Journal, 161, 605\u2013610.","journal-title":"American Heart Journal"},{"key":"9459_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","volume":"29","author":"SF Zhou","year":"2007","unstructured":"Zhou, S. F., Xue, C. C., Yu, X. Q., Li, C., & Wang, G. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring, 29, 687\u2013710.","journal-title":"Therapeutic Drug Monitoring"},{"key":"9459_CR37","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/heartjnl-2012-301892","volume":"98","author":"KW Park","year":"2012","unstructured":"Park, K. W., Kang, J., Park, J. J., Yang, H. M., Lee, H. Y., Kang, H. J., et al. (2012). Amlodipine, clopidogrel and CYP3A5 genetic variability: Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart, 98, 1366\u20131372.","journal-title":"Heart"},{"key":"9459_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jacc.2010.04.008","volume":"56","author":"PA Gurbel","year":"2010","unstructured":"Gurbel, P. A., Tantry, U. S., Shuldiner, A. R., & Kereiakes, D. J. (2010). Genotyping: One piece of the puzzle to personalize antiplatelet therapy. Journal of the American College of Cardiology, 56, 112\u2013116.","journal-title":"Journal of the American College of Cardiology"},{"key":"9459_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2014-01-512723","volume":"124","author":"NC Chan","year":"2014","unstructured":"Chan, N. C., Eikelboom, J. W., Ginsberg, J. S., Lauw, M. N., Vanassche, T., Weitz, J. I., et al. (2014). Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood 124, 689\u2013699.","journal-title":"Blood"},{"key":"9459_CR40","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., et al. (2009). Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 119, 2553\u20132560.","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s12012-018-9475-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000}}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-018-9459-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:37:56Z","timestamp":1751632676000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-018-9459-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["9459"],"URL":"https:\/\/doi.org\/10.1007\/s12012-018-9459-x","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"18 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a typo in the co-author name.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflict of interest to declare in relation to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}